N-Acetyl Transferase (NAT) 2 Polymorphisms and Susceptibility to Antituberculosis Drug-induced Hepatotoxicity in Indonesia
Keywords:
TB, NAT2, Polymorphisms, slow acetylators, drug-induced hepatotoxicity.Abstract
Tuberculosis (TB) treatment, based on the use of isoniazid (INH), rifampicin (RMP) and pyrazinamide (PZA), shown to cause drug-induced hepatotoxicity (DIH). Recent studies have demonstrated that genetic variations may associate with the risk of DIH, such as INH acetylation status, related to N-acetyl transferase (NAT) 2 polymorphism, which slow acetylation are more prone to side effects from drugs. The proportion of rapid and slow acetylator vary remarkably in populations of different ethnic or geographic origin which has been described in the various study, but, there is still limited information on our population. The objective of this study is to investigate the contribution of NAT2 polymorphisms to the anti-TB DIH in our population. This case-control study conducted at the Cipto Mangunkusumo Hospital, Jakarta and Omni Hospital Alam Sutera, Tangerang, Indonesia from January 2015
References
[ 1 ] Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of Clinical and Immunogenetic Risk Factors for the Development of Hepatotoxicity during Antituberculosis Treatment. 2002;166(7):916-9.
[ 2 ] Satyaraddi A, Velpandian T, Sharma SK, Vishnubhatla S, Sharma A, Sirohiwal A, et al. Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. The International Journal of Tuberculosis and Lung Disease. 2014;18(2):188-95.
[ 3 ] Wang PY, Xie SY, Hao Q, Zhang C, Jiang BF. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis [Review article]. The International Journal of Tuberculosis and Lung Disease. 2012;16(5):589-95.
[ 4 ] Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opinion on Drug Safety. 2006;5(2):231-49.
[ 5 ] Huang Y-S. Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury. Journal of the Chinese Medical Association. 2014;77(4):169-73.
[ 6 ] Tostmann A, Boeree MJ, Aarnoutse RE, Lange WCMD, Ven AJAMVD, Dekhuijzen R. Antituberculosis drug?induced hepatotoxicity: Concise up?to?date review. Journal of Gastroenterology and Hepatology. 2008;23(2):192-202.
[ 7 ] Steele MA, Burk RF, DesPrez RM. Toxic Hepatitis with Isoniazid and Rifampin: A Meta-analysis. Chest. 1991;99(2):465-71.
[ 8 ] Arbex MA, Varella MdCL, Siqueira HRd, Mello FAFd. Drogas antituberculose: intera
[ 9 ] Gupta VH, Amarapurkar DN, Singh M, Sasi P, Joshi JM, Baijal R, et al. Association of N?acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug?induced hepatotoxicity in Western India. Journal of Gastroenterology and Hepatology. 2013;28(8):1368-74.
[ 10 ] Huang YS. Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury. Expert Opinion on Drug Metabolism & Toxicology. 2007;3(1):1-8.
[ 11 ] Forestiero FJ, Cecon L, Hirata MH, de Melo FF, Cardoso RF, Cerda A, et al. Relationship of NAT2, CYP2E1 and GSTM1/GSTT1 polymorphisms with mild elevation of liver enzymes in Brazilian individuals under anti-tuberculosis drug therapy. Clinica Chimica Acta. 2013;415:215-9.
[ 12 ] Possuelo LG, Castelan JA, de Brito TC, Ribeiro AW, Cafrune PI, Picon PD, et al. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. European Journal of Clinical Pharmacology. 2008;64(7):673.
[ 13 ] Sim E, Walters K, Boukouvala S. Arylamine N-acetyltransferases: From Structure to Function. Drug Metabolism Reviews. 2008;40(3):479-510.
[ 14 ] Sabbagh A, Darlu P. SNP selection at the NAT2 locus for an accurate prediction of the acetylation phenotype. Genet Med. 2006;8(2):76-85.
[ 15 ] Hein DW, Doll MA. Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. Pharmacogenomics. 2012;13(1):31-41.
[ 16 ] Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11(2):272-6.
[ 17 ] Singh J, Arora A, Garg PK, Thakur VS, Pande JN, Tandon RK. Antituberculosis treatment-induced hepatotoxicity: role of predictive factors. Postgraduate Medical Journal. 1995;71(836):359-62.
[ 18 ] Lee SW, Chung LSC, Huang HH, Chuang TY, Liou YH, Wu LSH. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. The International Journal of Tuberculosis and Lung Disease. 2010;14(5):622-6.
[ 19 ] Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 2002;35(4):883-9.
[ 20 ] Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. The International Journal of Tuberculosis and Lung Disease. 2000;4(3):256-61.
[ 21 ] Cojutti P, Duranti S, Isola M, Baraldo M, Viale P, Bassetti M, et al. Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB? Journal of Antimicrobial Chemotherapy. 2016;71(5):1323-9.
[ 22 ] Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, Jakob V, Rodamer M, et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother. 2005;49(5):1733-8.
[ 23 ] Xiang Y, Ma L, Wu W, Liu W, Li Y, Zhu X, et al. The Incidence of Liver Injury in Uyghur Patients Treated for TB in Xinjiang Uyghur Autonomous Region, China, and Its Association with Hepatic Enzyme Polymorphisms NAT2, CYP2E1, GSTM1 and GSTT1. PLoS ONE. 2014;9(1):e85905.
[ 24 ] Yamada S, Tang M, Richardson K, Halaschek-Wiener J, Chan M, Cook VJ, et al. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics. 2009;10(9):1433-45.
[ 25 ] Kim SH, Bahn JW, Kim YK, Chang YS, Shin ES, Kim YS, et al. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics. 2009;10(11):1767-79.
[ 26 ] Mushiroda T, Yanai H, Yoshiyama T, Sasaki Y, Okumura M, Ogata H, et al. Development of a prediction system for anti-tuberculosis drug-induced liver injury in Japanese patients. Human Genome Variation. 2016;3:16014.
[ 27 ] Hiratsuka M, Kishikawa Y, Takekuma Y, Matsuura M, Narahara K, Inoue T, et al. Genotyping of the N-acetyltransferase2 Polymorphism in the Prediction of Adverse Drug Reactions to Isoniazid in Japanese Patients. Drug Metabolism and Pharmacokinetics. 2002;17(4):357-62.
[ 28 ] Azuma J, Ohno M, Kubota R, Yokota S, Nagai T, Tsuyuguchi K, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy. European Journal of Clinical Pharmacology. 2013;69(5):1091-101.
[ 29 ] Lee WM. Drug-Induced Hepatotoxicity. New England Journal of Medicine. 2003;349(5):474-85.
[ 30 ] Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. 2006;174(8):935-52.
[ 31 ] Sarma G, Immanuel C, Kailasam S, Narayana A, Venkatesan P. Rifampin-lnduced Release of Hydrazine from Isoniazid. American Review of Respiratory Disease. 1986;133(6):1072-5.
Downloads
Published
How to Cite
Issue
Section
License
Authors who submit papers with this journal agree to the following terms.
